OncoKB™ is a comprehensive precision oncology knowledge base developed at Memorial Sloan Kettering Cancer Center that annotates the oncogenic effects and clinical actionability of somatic alterations in cancer. OncoKB™ assigns evidence-based levels of clinical actionability to individual mutational events in a tumor type-specific context. As of 2024, OncoKB™ contains annotations for >7500 alterations in >850 cancer-associated genes.

In October 2021, OncoKB™ became partially FDA recognized as a public human genetic variant database to support clinical validity for genetic and genomic-based in vitro diagnostics.

As of 2024, OncoKB™ has published two articles that outline the precision oncology cancer therapy landscape and detail how OncoKB™ integrates within this landscape: 
• Suehnholz, et al. Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer. Cancer Discovery, 2023.
• Chakravarty, et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017.

OncoKB™ offers licenses for academic, commercial and hospital use, with which users can programmatically access the web API. Please visit our website for inquiries regarding licenses.

OncoKB

Org chart

Teams

Offices